Hepatocellular carcinoma

Nature Reviews Disease Primers, Journal Year: 2021, Volume and Issue: 7(1)

Published: Jan. 21, 2021

Language: Английский

---

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

The Lancet, Journal Year: 2017, Volume and Issue: 389(10088), P. 2492 - 2502

Published: April 21, 2017

Language: Английский

---

Hepatocellular Carcinoma

New England Journal of Medicine, Journal Year: 2019, Volume and Issue: 380(15), P. 1450 - 1462

Published: April 10, 2019

Primary liver cancer is the fourth most common tumor worldwide. Hepatocellular carcinoma occurs mainly in context of cirrhosis, hepatitis B or C virus infection, nonalcoholic steatohepatitis. Underlying disease limits therapeutic efficacy.

Language: Английский

---

A global view of hepatocellular carcinoma: trends, risk, prevention and management

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2019, Volume and Issue: 16(10), P. 589 - 604

Published: Aug. 22, 2019

Language: Английский

---

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet, Journal Year: 2016, Volume and Issue: 389(10064), P. 56 - 66

Published: Dec. 5, 2016

Language: Английский

---

BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

Journal of Hepatology, Journal Year: 2021, Volume and Issue: 76(3), P. 681 - 693

Published: Nov. 19, 2021

Language: Английский

---

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

New England Journal of Medicine, Journal Year: 2018, Volume and Issue: 379(1), P. 54 - 63

Published: July 4, 2018

Cabozantinib inhibits tyrosine kinases, including vascular endothelial growth factor receptors 1, 2, and 3, MET, AXL, which are implicated in the progression of hepatocellular carcinoma development resistance to sorafenib, standard initial treatment for advanced disease. This randomized, double-blind, phase 3 trial evaluated cabozantinib as compared with placebo previously treated patients carcinoma.

Language: Английский

---

Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

Hepatology International, Journal Year: 2017, Volume and Issue: 11(4), P. 317 - 370

Published: June 15, 2017

There is great geographical variation in the distribution of hepatocellular carcinoma (HCC), with majority all cases worldwide found Asia–Pacific region, where HCC one leading public health problems. Since "Toward Revision Asian Pacific Association for Study Liver (APASL) Guidelines" meeting held at 25th annual conference APASL Tokyo, newest guidelines treatment published by has been discussed. This latest recommend evidence-based management and are considered suitable universal use which a diversity medical environments.

Language: Английский

---

Molecular therapies and precision medicine for hepatocellular carcinoma

Nature Reviews Clinical Oncology, Journal Year: 2018, Volume and Issue: 15(10), P. 599 - 616

Published: July 30, 2018

Language: Английский

---

Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma

Gastroenterology, Journal Year: 2016, Volume and Issue: 150(4), P. 835 - 853

Published: Jan. 12, 2016

Language: Английский

---